Gordian Bio released a scientific preprint describing a scalable in‑vivo mosaic screening platform designed to establish causal links between genes and disease biology, according to the company. The platform integrates barcoded delivery of CRISPR perturbations with high‑throughput single‑cell readouts in living organisms.
The company says the technology enables parallel testing of many genetic perturbations in the same animal, improving experimental efficiency and reducing variation compared with traditional one‑gene‑at‑a‑time methods. According to Gordian Bio, the platform is intended to accelerate identification of genes that drive disease processes and support discovery of new therapeutic targets.
The platform employs barcoded CRISPR libraries delivered via viral vectors to induce genetic changes across many loci, with single‑cell RNA sequencing used to measure the effects in diverse tissue types. The company claims this approach allows causal inference of gene function in complex in‑vivo environments.
Gordian Bio states that the preprint is intended to share methodology with the scientific community ahead of formal peer review and publication. The company says the platform could be applied broadly across biology and disease areas to streamline target discovery and validation.
